In another study, TP53 mutation, and as a result, its overexpression were not common events in a group of 62 children with de novo ALL (14.5%), and alone, it could not be considered as strong independent predictors of outcome; however, p53 alterations were associated with the resistance to the induction therapy with prednisone [342]. The gene discussed is TP53; the disease is acute lymphoblastic leukemia.